We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+22.43%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$113M
AUM Growth
–
Cap. Flow
+$108M
Cap. Flow %
95.04%
Top 10 Hldgs %
61.67%
Holding
31
New
31
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$9.29M
2
BLUE
bluebird bio
BLUE
+$7.71M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.6M
4
SAGE
Sage Therapeutics
SAGE
+$7.08M
5
LOXO
Loxo Oncology, Inc
LOXO
+$6.75M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 77.28%
2 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$10.9M 9.6%
+412,500
New +$9.29M
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$8.34M 7.37%
+143,011
New +$7.08M
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
$7.16M 6.32%
+251,500
New +$6.75M
CTMX icon
4
CytomX Therapeutics
CTMX
$686M
$6.7M 5.92%
+321,023
New +$5.08M
ONCE
5
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$6.57M 5.81%
+145,000
New +$7.6M
BLUE
6
DELISTED
bluebird bio
BLUE
$6.42M 5.67%
+7,720
New +$7.71M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$1.84B
$6.26M 5.54%
+96,500
New +$6.33M
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.92M 5.23%
+403,872
New +$4.94M
GHDX
9
DELISTED
Genomic Health, Inc.
GHDX
$5.81M 5.13%
+165,000
New +$4.42M
ILMN icon
10
Illumina
ILMN
$30.2B
$5.76M 5.09%
+30,840
New +$4.98M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$29.1B
$5.65M 4.99%
+60,000
New +$5.56M
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$5.33M 4.71%
+332,500
New +$4.93M
VYGR icon
13
Voyager Therapeutics
VYGR
$179M
$5.19M 4.58%
+236,862
New +$5.46M
ILMN icon
14
CALL
Illumina
ILMN
$30.2B
$3.84M 3.39%
+20,560
New +$3.32M
BIIB icon
15
Biogen
BIIB
$29.7B
$2.76M 2.44%
+9,000
New +$2.59M
FMI
16
DELISTED
Foundation Medicine, Inc.
FMI
$2.42M 2.14%
+115,000
New +$2.22M
GNMK
17
DELISTED
GenMark Diagnostics, Inc
GNMK
$2.41M 2.13%
+310,000
New +$2.38M
BMY icon
18
Bristol-Myers Squibb
BMY
$133B
$2.21M 1.96%
+32,164
New +$2.13M
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.1M 1.86%
+65,000
New +$2.81M
NVTA
20
DELISTED
Invitae Corporation
NVTA
$2.05M 1.81%
+250,000
New +$1.97M
KITE
21
DELISTED
Kite Pharma, Inc.
KITE
$1.85M 1.63%
+30,000
New +$2.11M
DXCM icon
22
DexCom
DXCM
$32.7B
$1.39M 1.23%
+68,000
New +$1.41M
BLUE
23
CALL
DELISTED
bluebird bio
BLUE
$1.28M 1.13%
+1,544
New +$1.54M
OSUR icon
24
OraSure Technologies
OSUR
$286M
$1.09M 0.97%
+170,000
New +$971K
OXFD
25
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$863K 0.76%
+75,000
New +$928K
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Casdin Capital, which disclosed 31 positions worth $113M. Its ten largest holdings account for 62% of the portfolio.

Its largest position is Blueprint Medicines: 412,500 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, followed by Industrials.

  • Casdin Capital's largest Q4 2015 buy was Blueprint Medicines: 412,500 shares worth $10.9M.
  • Casdin Capital's ten largest holdings make up 62% of its $113M portfolio in Q4 2015.
  • Casdin Capital disclosed 31 positions in Q4 2015, its first 13F filing on record.

Based on Casdin Capital's 13F filing for Q4 2015, filed 8 Feb 2016.